TREMFYA® is the first FDA-approved medication of its kind to selectively block IL-23 for adults with moderate to severe plaque psoriasis.
Janssen Biotech, Inc., redefines the standard of care in immunology, nephrology, and oncology. Built upon a pioneering history, Janssen Biotech, Inc. harnesses innovations in large-molecule and small-molecule research to create important new therapeutic options. Beyond its innovative medicines, Janssen Biotech, Inc. is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates, and healthcare professionals have access to the latest treatment information, support services, and quality care.
For more information about Janssen Biotech, Inc., visit www.janssenbiotech.com.